Updated Jul 16, 2026
Mehta Vimal has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $22K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-18 | BTAI | BioXcel Therapeutics, Inc. | M — Option exercise | 219 | — | |
| 2026-05-22 | BTAI | BioXcel Therapeutics, Inc. | S — Open-market sale | 19.4K | $1.09 | $21K |
| 2026-05-22 | BTAI | BioXcel Therapeutics, Inc. | M — Option exercise | 49.8K | — | |
| 2026-05-07 | BTAI | BioXcel Therapeutics, Inc. | M — Option exercise | 18.0K | — | |
| 2026-03-17 | BTAI | BioXcel Therapeutics, Inc. | M — Option exercise | 219 | — | |
| 2026-03-17 | BTAI | BioXcel Therapeutics, Inc. | M — Option exercise | 164 | — | |
| 2025-09-14 | BTAI | BioXcel Therapeutics, Inc. | M — Option exercise | 219 | — | |
| 2025-09-14 | BTAI | BioXcel Therapeutics, Inc. | M — Option exercise | 163 | — | |
| 2025-07-22 | BTAI | BioXcel Therapeutics, Inc. | A — Grant or award | 15.6K | — | |
| 2024-12-17 | BTAI | BioXcel Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.1K | $0.36 | $773 |
| 2024-12-17 | BTAI | BioXcel Therapeutics, Inc. | S — Open-market sale [10b5-1] | 983 | $0.36 | $358 |
| 2024-12-17 | BTAI | BioXcel Therapeutics, Inc. | M — Option exercise [10b5-1] | 3.5K | — | |
| 2024-12-17 | BTAI | BioXcel Therapeutics, Inc. | M — Option exercise [10b5-1] | 2.6K | — |
Mehta Vimal is a corporate insider — currently tracked as CEO and President, Director of BioXcel Therapeutics, Inc. (BTAI). InsiderAlpha tracks every SEC Form 4 filing in real time.
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($22K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Mehta Vimal profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.